AZD 9793
Alternative Names: AZD-9793Latest Information Update: 18 Jun 2025
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Trispecific antibodies
- Mechanism of Action CD8 antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Liver cancer
Most Recent Events
- 25 Apr 2025 Adverse events and pharmacodynamics data from a preclinical studies in Solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 27 Mar 2025 Phase-I/II clinical trials in Liver cancer (Late-stage disease, Metastatic disease, Monotherapy, Recurrent, Inoperable/Unresectable) in USA (IV) (NCT06795022)
- 27 Mar 2025 Phase-I/II clinical trials in Liver cancer (Monotherapy, Metastatic disease, Late-stage disease, Recurrent, Inoperable/Unresectable) in USA (SC) (NCT06795022)